Boothbay Fund Management, LLC Biocryst Pharmaceuticals Inc Transaction History
Boothbay Fund Management, LLC
- $4.45 Billion
- Q2 2025
A detailed history of Boothbay Fund Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 274,127 shares of BCRX stock, worth $2.29 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
274,127
Previous 1,324,221
79.3%
Holding current value
$2.29 Million
Previous $9.93 Million
75.27%
% of portfolio
0.06%
Previous 0.3%
Shares
11 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$172 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$71 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$70.7 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$47.7 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.55B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...